Teixobactin was discovered by scientists over ten years ago, sparking hope for new antibiotics. Recent research from 2026 now gives a better idea of what it can do, how it works, and why it still isn’t available for patients.
Teixobactin is an experimental antibiotic found in a soil bacterium called Eleftheria terrae, which was once hard to grow in the lab. The discovery was published in Nature in January 2015.
Teixobactin works well against Gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA). Scientists have also seen it work against Mycobacterium tuberculosis in laboratory tests.
Teixobactin attacks key parts of the bacterial cell envelope, going after molecules called lipid II and lipid III, and it also disrupts bacterial membranes.
Resistance can still happen. At first, experiments did not find resistant bacteria, but a 2025 study showed that bacteria can become more tolerant after being exposed to teixobactin for a long time.
As of October 2026, teixobactin is still experimental. There is no proof yet from clinical trials that it is safe or effective in people.
An Encouraging Discovery in the Fight Against Antibiotic Resistance
Imagine getting a serious bacterial infection and finding out that several common antibiotics no longer help.
For people with drug-resistant infections, this is already a real and serious problem.
Antibiotic resistance happens when bacteria find ways to survive drugs that used to kill them or stop their growth. Treating these infections can be harder, may mean longer hospital stays, and sometimes involves medicines with more side effects.
This problem is so serious that the World Health Organization (WHO) keeps a list of top-priority bacteria to help guide antibiotic research.
The 2024 Bacterial Priority Pathogens List names dangerous drug-resistant bacteria, such as MRSA, carbapenem-resistant Acinetobacter baumannii, resistant Enterobacterales, and rifampicin-resistant tuberculosis.
Scientists urgently need antibiotics that work in new ways.
Teixobactin is a promising example. Its discovery showed that soil microbes might still have useful antibacterial compounds that regular lab methods have missed.
Teixobactin caused a lot of excitement, but over ten years of research have shown that finding a strong antibiotic is just the first step in making a safe and effective medicine.
What Is Teixobactin?
Teixobactin is a naturally occurring antibacterial compound produced by Eleftheria terrae, a soil bacterium identified through innovative cultivation techniques.
Researchers reported its discovery on January 7, 2015, in the scientific journal Nature.
The first study, titled “A new antibiotic kills pathogens without detectable resistance,” was led by Losee L. Ling and colleagues, including researchers associated with Northeastern University and other institutions.
Teixobactin belongs to a family of molecules called depsipeptides, which contain amino-acid building blocks connected through peptide and ester bonds.
What made this antibiotic particularly interesting was not simply its antibacterial activity.
It appeared to interfere with bacterial cell-wall construction in a way that might make it harder for bacteria to develop conventional resistance mechanisms.
In the initial experiments, researchers could not isolate teixobactin-resistant mutants of Staphylococcus aureus or Mycobacterium tuberculosis under the conditions tested.
That finding attracted worldwide scientific attention.
However, failing to obtain resistant bacteria in specific experiments does not prove that resistance can never develop.
How Scientists Discovered Teixobactin Using the iChip
For decades, scientists have searched soil samples for microorganisms that produce antibiotics.
Penicillin, streptomycin, and numerous other antibacterial compounds helped establish the importance of natural products in medicine.
Yet a major technical problem remained.
Many environmental bacteria are difficult to grow using standard laboratory cultivation methods.
As a result, conventional antibiotic-discovery approaches can overlook a large portion of microbial diversity.
Bringing the Natural Environment Into the Laboratory
The research team used a cultivation technology known as the isolation chip, or iChip.
Instead of relying exclusively on conventional laboratory growth conditions, this device lets microorganisms grow in small compartments while staying exposed to nutrients and chemical signals from their natural environment.
The approach assists researchers cultivate organisms that otherwise might not grow successfully in laboratory dishes.
Using methods designed to explore previously uncultured bacteria, researchers identified Eleftheria terrae and isolated teixobactin.
The discovery showed that developing new ways to cultivate microorganisms can reveal antibacterial compounds older screening techniques might miss.
Teixobactin was therefore both a prospective antibiotic candidate and an important example of innovation in drug discovery.
Original research: Ling et al., Nature (2015).
How Does Teixobactin Kill Bacteria?
Most antibiotics interfere with essential bacterial functions, such as protein synthesis, DNA replication, or cell-wall construction.
Teixobactin primarily targets the bacterial cell envelope, which supports maintaining the organism’s structure and integrity.
Its mechanism includes two important molecular targets:
1. Lipid II: An Essential Building Block of the Cell Wall
Bacteria use a strong structural material called peptidoglycan to construct their cell walls.
Lipid II is a key precursor that delivers peptidoglycan building blocks to the growing cell wall.
Teixobactin binds to lipid II and prevents it from performing its normal function.
Without access to this essential building material, susceptible bacteria cannot maintain normal cell-wall synthesis.
2. Lipid III: Another Important Cell-Envelope Precursor
Teixobactin also interacts with lipid III, a molecule involved in synthesizing wall teichoic acids in certain Gram-positive bacteria.
By interacting with these conserved cell-envelope components, teixobactin is able to disrupt pathways essential for microbial survival.
3. Disrupting the Bacterial Membrane
Research published in Nature in 2022 revealed that teixobactin’s activity is more sophisticated than simply blocking cell-wall construction.
Scientists found that teixobactin molecules can assemble into larger structures when interacting with lipid II.
These assemblies sequester lipid II and disrupt bacterial membrane organization.
The effects can compromise membrane integrity and contribute to bacterial death.
This combination of interfering with cell-wall synthesis and damaging the bacterial membrane makes teixobactin scientifically distinctive.
Researchers reported these data in “Teixobactin kills bacteria by a two-pronged attack on the cell envelope,” published in Nature (2022).
Although this mechanism offers encouraging possibilities for selective antibacterial activity, laboratory findings cannot replace the safety testing required in humans.
Which Superbugs Can Teixobactin Fight?
Teixobactin is particularly active against several Gram-positive bacteria, a group defined by particular cell-envelope structures.
These bacteria include important human pathogens responsible for skin infections, pneumonia, bloodstream infections, and other serious diseases.
Laboratory studies have demonstrated activity against several clinically significant organisms.
| Bacterium | Why it matters | Teixobactin evidence |
| MRSA | Can cause difficult-to-treat skin, bloodstream, and other infections | Strong laboratory activity and encouraging animal-model findings |
| Streptococcus pneumoniae | Causes pneumonia, meningitis, and bloodstream infections | Antibacterial activity and encouraging animal-model evidence |
| Clostridioides difficile | Can cause severe antibiotic-associated intestinal disease | Laboratory activity reported |
| Mycobacterium tuberculosis | Causes tuberculosis, including drug-resistant forms | Laboratory activity reported; not established as a human TB treatment |
The results are promising, but they do not mean teixobactin can currently treat these infections in patients.
Why Teixobactin Does Not Work Against Most Gram-Negative Bacteria
A main limitation is that natural teixobactin has limited activity against most Gram-negative bacteria.
Gram-negative organisms possess an additional outer membrane that restricts access to many antibacterial molecules.
This barrier protects organisms such as Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii from many antibiotics.
Unfortunately, several of these microbes are among the most urgent antibiotic-resistance threats.
Therefore, teixobactin is not a universal solution to the superbug crisis.
Researchers would need to overcome substantial biological barriers to extend teixobactin-based compounds’ activity to Gram-negative organisms.
Can Bacteria Develop Resistance to Teixobactin?
One of teixobactin’s most widely discussed attribute is its apparently high barrier to bacterial resistance.
In the first 2015 study, researchers could not obtain resistant mutants in certain bacteria they tested.
This observation mattered because teixobactin targets highly conserved molecules crucial for bacterial viability.
Bacteria may find it harder to modify these molecules without jeopardizing key biological functions.
However, scientific evidence has become increasingly nuanced.
What a 2025 Study Revealed About Antibiotic Tolerance
A study published in Antimicrobial Agents and Chemotherapy in November 2025 examined what happened when researchers repeatedly exposed Enterococcus faecalis to teixobactin.
The researchers found that prolonged exposure could produce bacterial populations with substantially increased tolerance to the antibiotic.
Importantly, the study distinguished antibiotic tolerance from antibiotic resistance.
- Resistance: Bacteria can grow at antibiotic concentrations that would normally inhibit them.
- Tolerance: Bacteria survive antibiotic exposure longer without necessarily becoming able to grow at much higher drug concentrations.
The researchers did not demonstrate high-level teixobactin resistance in these experiments.
However, some adapted bacteria became more tolerant to other cell-envelope-targeting antibiotics, including penicillin G and daptomycin.
This phenomenon is known as cross-tolerance.
The finding does not mean teixobactin has failed as a potential antibiotic.
Instead, it demonstrates why scientists have to carefully investigate bacterial adaptation before assuming any new drug will remain effective indefinitely.
Study: Darnell et al., “Prolonged exposure to teixobactin generates cross-tolerance to other cell wall-targeting antimicrobials in Enterococcus faecalis” (2025).
What Does the Latest October 2026 Research Reveal?
A scientific review published on October 9, 2026, provides an updated assessment of teixobactin research.
The review, titled “From Soil to Shelf: Teixobactin at Ten—Mechanism, SAR, and the Road to Clinical Application,” appeared in ACS Infectious Diseases.
Renaud Binette and colleagues authored the paper, which examined more than a decade of research into teixobactin’s molecular structure, antibacterial mechanism, modified derivatives, and prospects for clinical development.
The review identified several important developments.
Scientists Better Understand How Teixobactin Works
Modern structural and biophysical research has helped explain how teixobactin interacts with bacterial cell-envelope precursors and forms molecular assemblies.
This understanding may support more rational antibiotic design.
Rather than relying on trial and error, researchers can investigate which structural features drive antibacterial activity.
Modified Versions May Improve Drug Development
Scientists have synthesized numerous teixobactin analogs: chemically modified versions of the original compound.
Some modifications seek to simplify synthesis, improve antibacterial potency, or address formulation challenges.
Researchers have also explored substitutions for amino-acid components that are particularly challenging to manufacture.
However, greater potency in a laboratory assay does not automatically translate into a better antibiotic for patients.
A successful drug must also have suitable stability, distribution, tolerability, and pharmacological properties.
Formulation Is Still a Major Challenge
An unusual feature of teixobactin is its tendency to assemble into bigger molecular structures.
This behavior contributes to its antibacterial mechanism, but it can also obstruct efforts to formulate the compound into a reliable pharmaceutical product.
Researchers must preserve antibacterial activity while making the compound suitable for manufacturing, administration, and consistent dosing.
The October 2026 review states that these scientific problems, along with economic and regulatory obstacles, remain major barriers to clinical development.
Why Hasn’t Teixobactin Become an Approved Antibiotic?
Teixobactin was discovered in 2015, so it is reasonable to wonder why it has not already become a medicine.
The answer illustrates the enormous difference between discovering antibacterial activity and successfully developing an antibiotic.
1. Human Safety Has Not Been Established
A compound that kills bacteria in laboratory experiments may still produce unwanted effects in the human body.
Researchers need to investigate potential toxicity, organ effects, immune reactions, and other safety concerns.
Early animal results are useful but cannot conclusively predict human safety.
2. Effective Drug Delivery Is Challenging
An antibiotic must reach the infection site at sufficient concentrations without causing unacceptable toxicity.
Scientists must understand how the body absorbs, distributes, metabolizes, and eliminates the compound.
These properties are especially important for treating infections in different tissues and organs.
3. Manufacturing Must Be Practical
Teixobactin has a complex molecular structure.
Producing complex antibiotic molecules in sufficient purity, quantity, and consistency can present manufacturing challenges.
Researchers are investigating modified compounds because simpler, more practical versions may be easier to develop.
4. Clinical Trials Are Essential
Before an experimental antibiotic can become a routine treatment, developers generally need human studies to investigate safety, dosing, effectiveness, and adverse effects.
Encouraging results against laboratory bacteria or infections in mice are not sufficient evidence for prescribing a drug to patients.
As of October 29, 2026, the research reviewed for this article does not establish teixobactin as an antibiotic tested successfully in human clinical trials or approved for clinical use.
Why New Antibiotics Are Still Urgently Needed
Teixobactin is part of a much larger scientific effort to address antimicrobial resistance.
The challenge isn’t simply discovering more antibacterial molecules.
Scientists must find treatments that are sufficiently innovative, clinically useful, safe, and accessible.
In October 2025, WHO published an assessment of the global antibacterial development pipeline.
According to the report, the number of antibacterial agents in clinical development had declined from 97 in 2023 to 90 in 2025.
The same assessment reported that 17 new antibacterial agents aimed at priority bacterial pathogens had received marketing authorization since July 2017, but only two belonged to a new chemical class.
These findings show how difficult it is to deliver genuinely innovative treatments.
Read the WHO 2025 antibacterial development report.
Teixobactin shows why exploring new microbial sources and molecular targets matters.
Even if the first molecule never becomes an approved antibiotic, research into its mechanism and chemical structure could inform future antibacterial discoveries.
What Needs to Happen Next?
Several important questions remain unanswered before teixobactin-based medicines could become a realistic treatment option.
Researchers need to determine whether they can reliably manufacture promising derivatives, whether they have acceptable safety profiles, and whether sufficient concentrations can reach infected tissues.
Further experiments must also examine how bacterial tolerance and resistance might develop under clinically relevant conditions.
Finally, carefully designed human clinical trials would be required to establish whether a suitable candidate can safely and effectively treat bacterial infections.
The path from laboratory discovery to an approved medicine is demanding, and many experimental compounds never make it.
Nevertheless, the scientific knowledge generated along the way can contribute toward the broader development of new antibiotics.
Final Thoughts: A Scientific Breakthrough, but Not Yet a Medical Treatment
Teixobactin remains one of the most interesting examples of modern antibiotic discovery.
Its identification using innovative soil-bacteria cultivation methods opened a new avenue for finding natural antibacterial compounds.
Subsequent research revealed an unusual mechanism involving bacterial cell-wall precursors and membrane disruption.
More recent studies have also given a clearer knowledge of its limitations, including bacterial tolerance, formulation difficulties, and the challenges of developing modified compounds.
The most important lesson is that scientific prospect should not be confused with proven clinical benefit.
As of October 2026, teixobactin has not become an established treatment for drug-resistant infections.
However, the research continues to provide valuable insights into how scientists might discover and design future antibiotics.
For a world facing more and more hard-to-treat bacterial infections, that knowledge remains important.
References and Further Reading
- Ling, L. L., et al. (2015). A new antibiotic kills pathogens without detectable resistance. Nature, 517, 455–459.
https://doi.org/10.1038/nature14098 - Teixobactin kills bacteria by a two-pronged attack on the cell envelope (2022). Nature.
https://doi.org/10.1038/s41586-022-05019-y - Darnell, R. L., et al. (2025). Prolonged exposure to teixobactin generates cross-tolerance to other cell wall-targeting antimicrobials in Enterococcus faecalis. Antimicrobial Agents and Chemotherapy.
https://doi.org/10.1128/aac.00629-25 - Binette, R., Lacasse, E., Malouin, F., & Boudreault, P.-L. (2026). From Soil to Shelf: Teixobactin at Ten—Mechanism, SAR, and the Road to Clinical Application. ACS Infectious Diseases, 12(10), 3280–3295.
https://doi.org/10.1021/acsinfecdis.6c00389 - World Health Organization (2024). WHO bacterial priority pathogens list, 2024.
https://www.who.int/publications/i/item/9789240093461 - World Health Organization (2025). Analysis of antibacterial agents in clinical and preclinical development: overview and analysis 2025.
https://www.who.int/publications/i/item/9789240113091